Olivia Brayer
Stock Analyst at Cantor Fitzgerald
(2.98)
# 1,349
Out of 5,149 analysts
109
Total ratings
51.52%
Success rate
9.02%
Average return
Main Sectors:
Stocks Rated by Olivia Brayer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CTMX CytomX Therapeutics | Maintains: Overweight | $6 → $10 | $4.81 | +107.90% | 2 | Feb 4, 2026 | |
| INSM Insmed | Maintains: Overweight | $216 → $230 | $147.00 | +56.46% | 1 | Dec 16, 2025 | |
| IKT Inhibikase Therapeutics | Initiates: Overweight | $4 | $1.91 | +109.42% | 1 | Dec 11, 2025 | |
| VNDA Vanda Pharmaceuticals | Maintains: Overweight | $13 → $11 | $7.84 | +40.31% | 2 | Oct 30, 2025 | |
| GOSS Gossamer Bio | Reiterates: Overweight | n/a | $0.47 | - | 1 | Sep 11, 2025 | |
| UTHR United Therapeutics | Maintains: Overweight | $405 → $525 | $498.65 | +5.28% | 2 | Sep 10, 2025 | |
| BMRN BioMarin Pharmaceutical | Reiterates: Overweight | $90 | $58.53 | +53.77% | 15 | Feb 20, 2025 | |
| VRTX Vertex Pharmaceuticals | Reiterates: Overweight | $480 | $474.27 | +1.21% | 22 | Feb 11, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Neutral | $50 → $55 | $61.22 | -10.16% | 9 | Feb 4, 2025 | |
| GILD Gilead Sciences | Reiterates: Neutral | $80 | $147.83 | -45.88% | 10 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $11.64 | - | 1 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $1,015 | $766.66 | +32.39% | 8 | Oct 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $405 | $377.00 | +7.43% | 2 | Oct 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $220 | $318.65 | -30.96% | 23 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $10 | $14.15 | -29.33% | 5 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $6.5 | $2.93 | +122.22% | 4 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $72 | $58.06 | +24.01% | 1 | Apr 13, 2023 |
CytomX Therapeutics
Feb 4, 2026
Maintains: Overweight
Price Target: $6 → $10
Current: $4.81
Upside: +107.90%
Insmed
Dec 16, 2025
Maintains: Overweight
Price Target: $216 → $230
Current: $147.00
Upside: +56.46%
Inhibikase Therapeutics
Dec 11, 2025
Initiates: Overweight
Price Target: $4
Current: $1.91
Upside: +109.42%
Vanda Pharmaceuticals
Oct 30, 2025
Maintains: Overweight
Price Target: $13 → $11
Current: $7.84
Upside: +40.31%
Gossamer Bio
Sep 11, 2025
Reiterates: Overweight
Price Target: n/a
Current: $0.47
Upside: -
United Therapeutics
Sep 10, 2025
Maintains: Overweight
Price Target: $405 → $525
Current: $498.65
Upside: +5.28%
BioMarin Pharmaceutical
Feb 20, 2025
Reiterates: Overweight
Price Target: $90
Current: $58.53
Upside: +53.77%
Vertex Pharmaceuticals
Feb 11, 2025
Reiterates: Overweight
Price Target: $480
Current: $474.27
Upside: +1.21%
Bristol-Myers Squibb Company
Feb 4, 2025
Maintains: Neutral
Price Target: $50 → $55
Current: $61.22
Upside: -10.16%
Gilead Sciences
Dec 11, 2024
Reiterates: Neutral
Price Target: $80
Current: $147.83
Upside: -45.88%
Nov 14, 2024
Reiterates: Neutral
Price Target: n/a
Current: $11.64
Upside: -
Oct 23, 2024
Reiterates: Neutral
Price Target: $1,015
Current: $766.66
Upside: +32.39%
Oct 22, 2024
Reiterates: Overweight
Price Target: $405
Current: $377.00
Upside: +7.43%
Oct 11, 2024
Reiterates: Neutral
Price Target: $220
Current: $318.65
Upside: -30.96%
Sep 16, 2024
Reiterates: Overweight
Price Target: $10
Current: $14.15
Upside: -29.33%
May 9, 2024
Reiterates: Overweight
Price Target: $6.5
Current: $2.93
Upside: +122.22%
Apr 13, 2023
Initiates: Overweight
Price Target: $72
Current: $58.06
Upside: +24.01%